Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
The poster presentations will be available for download from the Events and Presentation page on the
Details of the Poster Presentations are as follows:
|Title:||Twyneo® (Microencapsulated Benzoyl Peroxide 3%, Tretinoin 0.1%) Phase 3 Efficacy and Safety: Results from Two Randomized Controlled Clinical Trials|
|Title:||Efficacy and Safety of Microencapsulated Benzoyl Peroxide (E-BPO) Cream, 5% in Papulopustular Rosacea: Results from Two Phase 3, Vehicle-Controlled Trials|
|Title:||Characterization of Microencapsulated Benzoyl Peroxide (E-BPO) for the Treatment of Papulopustular Rosacea|
The Twyneo poster debuted and was highlighted at the 17th Annual
About Papulopustular Rosacea
Papulopustular rosacea also known as inflammatory lesion of rosacea, is a chronic and recurrent inflammatory skin disorder that affects nearly 5 million Americans. The condition is common, especially in fair-skinned people of Celtic and northern European heritage. Onset is usually after age 30 and typically begins as flushing and subtle redness on the cheeks, nose, chin or forehead. If left untreated, rosacea can slowly worsen over time. As the condition progresses the redness becomes more persistent, blood vessels become visible and pimples often appear. Other symptoms may include burning, stinging, dry skin, plaques and skin thickening.
About Acne Vulgaris
Acne vulgaris is a common multifactorial skin disease that according to the American Academy of Dermatology affects approximately 40 to 50 million people in the
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo®, for the treatment of acne vulgaris, and Epsolay®, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor for the treatment of punctate palmoplantar keratoderma. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Chief Financial Officer
U.S. Investor Contact:
Chamberlain Healthcare PR
Source: Sol-Gel Technologies Ltd.